WO2009019323A2 - Utilisation de verre bioactif - Google Patents

Utilisation de verre bioactif Download PDF

Info

Publication number
WO2009019323A2
WO2009019323A2 PCT/FI2008/050449 FI2008050449W WO2009019323A2 WO 2009019323 A2 WO2009019323 A2 WO 2009019323A2 FI 2008050449 W FI2008050449 W FI 2008050449W WO 2009019323 A2 WO2009019323 A2 WO 2009019323A2
Authority
WO
WIPO (PCT)
Prior art keywords
bone
glass
bioactive
ceramic material
silica
Prior art date
Application number
PCT/FI2008/050449
Other languages
English (en)
Other versions
WO2009019323A3 (fr
Inventor
Ilkka Kangasniemi
Jouni HEIKKILÄ
Allan Aho
Original Assignee
Vivoxid Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivoxid Oy filed Critical Vivoxid Oy
Publication of WO2009019323A2 publication Critical patent/WO2009019323A2/fr
Publication of WO2009019323A3 publication Critical patent/WO2009019323A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/10—Ceramics or glasses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/12—Phosphorus-containing materials, e.g. apatite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow

Definitions

  • the present invention relates to a method for the treatment and prevention of bone resorption, especially when associated with osteoporosis or metallic permanent implants.
  • Bone fractures, bone defects and disease caused deficiencies may cause incurable states for a patient. Recurring fractures, bone resorption around implants and local bone loss leading to fractures and collapses of the bone structure are common phenomena especially amongst elderly and are typically caused by osteoporosis. Osteoporosis is a disease of bone in which the bone mineral density is reduced, bone micro architecture is disrupted, and the amount and variety of non-collagenous proteins in bone is altered. Typical fractures occur in the vertebral column, hip and wrist.
  • osteoporosis The underlying mechanism in all cases of osteoporosis is an imbalance between bone resorption and bone formation. Either bone resorption is excessive, and/or bone formation is diminished. Bone matrix is manufactured by the osteoblast cells, whereas bone resorption is accomplished by osteoclast cells.
  • Bone fractures and defects have been treated by using autologous (patients own) bone, allogenous bone (cadaver derived), growth factors, demineralized bone matrices, blood platelet derivatives or synthetic fillers as bone substitutes. These organic or synthetic materials aid the bone formation by providing a suitable substrate for bone cells to grow on, by stimulating the bone growth through their chemistry and even by stimulating the differentiation of bone cells from the stem cells.
  • the various materials have been used to stimulate the bone growth in short term, i.e. during the healing period of the actual cavity, fracture or other defect.
  • the filler material is considered merely as a nuisance because it may interfere with the future X-ray analysis of the site, thus making it more difficult to analyse whether the site has properly healed or not.
  • Most bone fillers are also brittle materials by nature and therefore do not contribute to the mechanical strength of the bone by themselves.
  • the healing period of bone has been considered as 16-24 weeks. The healing time may vary considerably even beyond 24 weeks and some times not healing at all depending on many variables such as age, general health, smoking habits, size and severity of defect, type of disease etc.
  • the general consensus has been that the bone filling materials should preferably disappear during the first year after implantation.
  • particles of bioactive glass in a size range of from about 200 micrometers to about 300 micrometers are implanted in bone tissue.
  • the particles are made from about 40 % to about 58 % silicon dioxide, from about 10 % to about 30 % sodium oxide, from about 10 % to about 30 % calcium oxide, and up to about 10 % phosphorous pentoxide, by weight.
  • the size range of the particles is selected such that the bioactive glass particles will become excavated from inside and degrade totally rapidly and therefore rapidly become replaced by bone. These particles are thus not meant to have a long term effect. No information is given that these glasses could exhibit a long term bone supporting function in a prophylactic manner, inhibiting renewed resorption of the bone at the implantation site.
  • bioactive bone cement compositions comprising a powder component including (a) strontium containing hydroxyapatite; and a liquid component including (b) bisphenol A diglycidylether dimethacrylate resin, (a) and (b) being formulated to create a settable fluid substance when mixed together.
  • Hydroxyapatite as a bone filler has in itself not been shown to exhibit a long term effect as a bone producing agent. Adding strontium into it increases the bone producing effect in osteoporotic defects by adjusting the activity of both osteoclast and osteoblast cells. Combining these with acrylic cement would make the material partially inert, while still having a limited amount of bioactivity as a suitable substrate for osteoblastic cells to adhere to and by releasing slowly strontium ions into the surrounding tissues.
  • the effect of the material is taught to be cement that increases bone growth onto its surface. This material can also be used in treatment of osteoporotic defects. The function of the material is also to repair the defect rather than prophylactically prevent a reoccurhng osteoporosis.
  • bioactive glass or silica based or silica containing substances in this purpose.
  • an artificial bone comprising calcium phosphate artificial bone cement and a polyphosphate.
  • the artificial bone is used as osteoconductive and osteoinductive biodegradable substitute for conventional bone cements, allografts, and autografts. It can be used for the treatment of defects and fractures in every bone of the body, as cure for osteoporosis, as fillers of implant for dental surgery, as bone substitute for plastic surgery, and as substitution of defected bones in the operation of joints (e.g., hip joint, knee joint and shoulder joint) and the operation of vertebra. It can also be used as filler, reinforcement, and support for vertebra plasty and oral graft operation.
  • the described artificial bone is non-toxic to the body and chemically stable, and promotes biocompatible osteoanagenesis. Neither prophylactic long term effect nor silica based materials are described.
  • Patent WO 2003/02431 shows a bone precursor composition comprising cement mixture or solid cement and a pore-forming agent.
  • the pore-forming agent has a particle size of 20 - 500 microM.
  • prophylactic long term effect nor silica based materials or bioactive glass are described.
  • a biomatehal (A1 ) comprising a bone compatible matrix material (a1 ) and an inhibitor of cell mediated acidification (b) is described.
  • This is a combination of CaP cement and an inhibitor of cell mediated acidification that may be useful in the treatment of osteoporotic defects.
  • prophylactic long term effect nor silica based materials are described.
  • Document WO 2002/068009 presents an orthopaedic composition
  • a shaped article e.g., bone plate, bone screws and load bearing intervertebral disc implant
  • a bone cement for orthopaedic applications
  • stabilizing a spine by associating with vertebrae of the spine, a shaped load bearing article formed from the composition
  • a shaped load bearing article formed from the composition for correcting bone defect by applying the composition to the bone defect.
  • It can be used to form various spinal implants including various spinal spacers and cages, as well as the bone plates and the bone screws. It can also be used for promoting fusion of adjacent vertebrae.
  • the composition has mechanical and biological properties.
  • a particulate ceramic e.g. hydroxyapatite in combination with other forms of calcium phosphate
  • the ceramic may advantageously promote bone apposition.
  • the cages may be strong due to the biphasic reinforcement structure, the cages may gradually lose their strength upon in vivo degradation and eventual resorption.
  • the cages formed of hydroxyapatite and/or other form of calcium phosphate in combination with the resorbable polymer the nanoparticles of the ceramic may buffer the acidic degradation products of the resorbable polymer.
  • the cages can be located in vivo radiographically due to the presence of hydroxyapatite and/or other calcium phosphates.
  • the ceramic may advantageously act as a support structure to enhance bone ingrowth in the composition, and in other forms, may act to reinforce the polymer it is combined with.
  • the nanometer-sized ceramic particles may be more beneficial in promoting bone ingrowth than larger particles, including those greater than 1 mum.
  • bioactive glass or CaP ceramic in a biodegradable/nonbiodegradable polymer for achieving a bioactive composite material.
  • the size of the particles ensures that they will dissolve from the composite almost as soon as they come into contact with the body fluids, i.e. water.
  • Polymers generally absorb water within the first weeks after implantation of the order of a few weight percentages of their dry weight or in case of biodegradable polymers more in time due to their biodegradation process which is usually selected to occur within a year. In the latter case it is clear that this material cannot have a long term effect. In the former case the presence may or may not be long term depending on the polymer component of the composite. However, again no mention has been made to the potential long term prophylactic effect of silica release.
  • Publication WO 94/04657 describes a bioactive material for in vitro inoculation of cells capable of attaining an osteoblastic phenotype, comprising a substrate with a surface capable of leaching ions, into a tissue culture medium. The surface is treated prior to inoculation under aqueous conditioning to render the substrate incapable of raising the pH of a tissue culture medium above physiological pH upon inoculation. It also describes implantable bone replacement comprising said substrate and bone tissue formed on the substrate in vitro by inoculation with cells capable of attaining an osteoblastic phenotype.
  • porous glass substrate for use in an implantable bone replacement comprising: (a) melting an admixture of SiO2, Na2O, CaO and P2O5; (b) quenching the method admixed to create a glass frit; (c) forming a glass powder from the glass frit; and (d) forming a porous glass substrate from the powder.
  • the porous glass thus formed exhibits no crystals.
  • the bioactive material is a glass with the composition of Si ⁇ 2 (40-50 weight-%), CaO (20-30 weight-%), Na 2 O (5-30 weight-%) and P 2 O 5 (0-12 weight- %).
  • the material is porous and has a porosity of 10-80 %.
  • the pore size is less than 800 ⁇ m.
  • the materials can be inserted into all areas of the body which exhibit increased risk of fracture and a decreased potential for bone tissue formation, e.g., as a result of osteoporosis.
  • This document thus describes a bioactive glass product that may have compositions and particle sizes capable of staying in the body for extended periods of time.
  • bone cells are differentiated in culture as a result of the ions leaching from the glass.
  • the combination of cells and glass scaffold is intended for high formation rates of extra cellular material to quickly heal the diseased bone. No mention is however made on the potential long term effect of the material in prophylactic prevention of osteoporosis as a result of the leaching ions from the material. After the bone has healed, i.e. it retains its more or less original shape, thickness and strength, the document does not mention any further benefit for the material.
  • Bone healing involves first osteoclast activity that leads to partial resorption of the damaged bone, followed by new bone formation that produces a slight excess amount of bone, which is not as well organised and dense as mature bone.
  • the last phase of bone healing involves a remodeling phase where bone cells slowly replace the newly formed bone with more organised and densely mineralised bone.
  • An object of the present invention is to provide a material suitable for the treatment and prevention of bone resorption.
  • the present invention relates to a method of using bioactive ceramic material for the treatment and prevention of bone resorption.
  • the present inventors have performed bone tumour filling studies in which the cavity created by the tumour surgery was filled with either autologous bone or bioactive glass S53P4.
  • the glass-side showed in three year follow up a higher bone thickness than the autologous bone side.
  • the autologous bone produced faster bone growth initially than the glass.
  • bioactive glass (BG) granules were compared with autogenous bone (AB) as bone filler in benign bone tumour surgery in patients with radiologically diagnosed benign cystic bone tumour.
  • Consecutive 25 patients 11 AB and 14 BG were operated between 1993 and 1997.
  • the two groups were identical with regard to age, race, type of tumour and location of tumour (big/small).
  • the evaluation was made using radiological and laboratory analysis.
  • bioactive glass S53P4 can be used as a bone substitute material in the treatment of benign cystic bone tumours, including adolescent patients.
  • Clinically S53P4 was well functioning, safe and well tolerated.
  • the main benefit from using the bioactive glass is that harvesting of the bone grafts can be avoided.
  • the study showed that in "healthy" subjects an effect of the glass can be seen as the thickening of the bone in time. The study does not reveal if any of the patients were simultaneously suffering from osteoporosis.
  • the effect of the glass can naturally last only as long as the glass exists in the operated area. Generally it is considered that the glass has its bone growth promoting effect through three mechanisms:
  • the glass needs to have a certain dissolution rate in order to be bioactive in the first two aspects it means that the glass will also dissolve at a rate enabling these effects. In turn this means that the glass compositions as well as the dissolution rates are limited to certain limits to achieve all three of these effects.
  • the relationship between the composition and the bioactivity has been described at least in three different ways that give the expert sufficient tools to design a bioactive glass. (Hench L. Bioactive ceramics: Theory and clinical applications. Bioceramics 1994;7:3-14).
  • the particle size or the surface area to volume ratio (SaA/).
  • SaA/ surface area to volume ratio
  • the commercially available glass 45S5/Bioglass is available in size range from 90-700 ⁇ m and it is claimed to vanish from the body in less than a year.
  • the present invention describes the use of bioactive glass compositions and particle sizes that are able to retain this long term bioactivity and their use in local treatment of osteoporosis or other bone reducing conditions.
  • Glass S53P4/BonAlive ® has a chemical composition of 53 weight-% Si ⁇ 2- Na2 ⁇ 23 weight-%, CaO 20 weight-% and P 2 O 5 4 weight-% that is a clearly slower dissolving glass than the 45S5 glass that has a composition of 45 weight-% SiO 2 , 24.5 weight-% Na 2 O, 24.5 weight-% CaO, and 6 weight-% P 2 O 5 .
  • dissolution products of the glass may influence the differentiation of cells into osteoblasts
  • glass dissolution products mainly silica is capable of mineralizing the surrounding bony tissues
  • the long term bone producing ability is however not dependent of the bone bonding ability and of the CaP surface formation. It is believed from the above four facts that it is the combination of the long term existence, release of silica and differentiation of the stem cells into osteoblasts that allow for the fourth fact. Therefore the fourth fact cannot be considered to be the based on the same invention as the other bioactivity parameters.
  • bioactive glass not only aids the formation of new bone, but also maintains the once formed new bone.
  • osteoporosis is stronger that the ability of forming new bone. Therefore, there exists a prejudice against the present invention, among the experts in the art. This belief is confirmed by the fact that at present, all materials for the treatment of osteoporosis are designed to last for a maximum of one year, i.e. it is not desired that the material remains after the first year.
  • the present invention relates to a method of using silica containing bioactive ceramic material for the treatment and prevention of bone resorption.
  • silica as the active agent in the prevention of the osteoporosis is that it is a natural substance rather than foreign substance in the human body.
  • said bone resorption is caused by osteoporosis, metallic implant, composite implant or trauma.
  • said bioactive ceramic material is selected such that the dissolution period is from 1 to 15 years.
  • the bioactive ceramic material is capable of releasing silica in amounts resulting in its sustained release for periods of longer than one year.
  • the bioactive ceramic material may be selected from the group consisting of bioactive glass, silica sol-gel glass, CaP ceramic material doped with Si ⁇ 2, CaNaP glass with addition of SiO2, Ti 1 Si sol gel material and mixtures thereof.
  • the bioactive glass has, for example, a composition of
  • Said bioactive glass composition may further comprise potassium, magnesium, boron, calcium peroxide or mixtures thereof.
  • bioactive glass compositions are for example
  • the bioactive glass has the composition of
  • SiO2 is 53 wt-%
  • Na2 ⁇ is 23 wt-%
  • CaO is 20 wt-%
  • P2O5 is 4 wt-%.
  • SiO2 is 51-56 wt-%
  • Na2 ⁇ is 7-9 wt-%
  • CaO is 21 -23 wt-%
  • K 2 O is 10-12 wt-%
  • MgO is 1 -4 wt-%
  • P2O5 is 0.5-1.5 wt-% and B2O3 is 0-1 wt-%
  • silica sol-gel glass When silica sol-gel glass is used, it may be doped with ions selected from the group consisting of calcium, phosphorus, sodium, magnesium, potassium, boron or mixtures thereof.
  • the silica content of the sol-gel glasses can be up to 100 weight-% and Ti 1 Si sol gel materials, the SiO2 content can vary between 0,1-100 weight-%.
  • CaP ceramic material it may be selected from the group consisting of hydroxyl phosphates, fluor phosphates, carbonated phosphates, apatite, tricalcium phosphates, amorphous CaP with the Ca/P ratio between 0,5-2,5 and mixtures thereof.
  • the material according to the present invention may be in any suitable form, such as particles, granules, fibres, coating, composite, blocks, scaffolds and mats or tissues.
  • the present invention relates to bioactive glass or ceramic particles of such size and compositions resulting in a) sustaining bone levels, b) increasing bone density and c) increasing cortical bone thickness i) after natural healing period, ii) for the entire period of the glass resorption, iii) for periods up to the lifetime of the patient, and iv) for periods up to and over 20 years.
  • the product according to the present invention may be used for the prevention of bone resorption around metallic and composite implants, in spinal, dental, orthopaedic and cranio maxillo facial injuries and defects as well as in injuries caused by trauma or sport.
  • the material according to the present invention may be either implanted within the bone in surgery or injected into the bone or near the bone, should surgery be undesirable. It is can thus be used in local treatment. It is believed to be sufficient to inject the material near the bone, as a hole in a bone further decreases its strength and increases the risk of infection, and may thus be undesirable. In case of surgery for treating collapsed vertebrae, the surrounding vertebrae are preferably treated in preventive manner at the same time.
  • the present invention further relates to a method for sustaining bone level, increasing bone density or increasing cortical bone thickness by implanting bioactive ceramic material in the bone or in the vicinity of the bone of a patient. The embodiments and variations presented above apply mutatis mutandis to this method.
  • the present invention further relates to a bioactive ceramic material capable of releasing silica in amounts resulting in its sustained release for periods of longer than one year.
  • a bioactive ceramic material capable of releasing silica in amounts resulting in its sustained release for periods of longer than one year.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ceramic Engineering (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Materials For Medical Uses (AREA)
  • Glass Compositions (AREA)

Abstract

La présente invention porte sur un procédé d'utilisation de silice contenant un matériau céramique bioactif pour le traitement et la prévention d'une résorption osseuse, notamment associée à une ostéoporose ou à des implants métalliques permanents.
PCT/FI2008/050449 2007-08-03 2008-08-01 Utilisation de verre bioactif WO2009019323A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95395707P 2007-08-03 2007-08-03
US60/953,957 2007-08-03

Publications (2)

Publication Number Publication Date
WO2009019323A2 true WO2009019323A2 (fr) 2009-02-12
WO2009019323A3 WO2009019323A3 (fr) 2009-12-10

Family

ID=39930528

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2008/050449 WO2009019323A2 (fr) 2007-08-03 2008-08-01 Utilisation de verre bioactif

Country Status (1)

Country Link
WO (1) WO2009019323A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102531385A (zh) * 2012-01-17 2012-07-04 上海中山医疗科技发展公司 一种生物活性玻璃及其制备方法
CN115006598A (zh) * 2021-03-03 2022-09-06 上海交通大学医学院附属第九人民医院 掺锶硅酸钙-丝蛋白复合材料制备方法与应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104743886A (zh) * 2015-03-31 2015-07-01 苏州维泰生物技术有限公司 生物活性玻璃陶瓷及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074009A1 (fr) * 2002-03-01 2003-09-12 Naerhi Timo Ciments au verre ionomere permettant d'ameliorer la mineralisation d'un tissu dur

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074009A1 (fr) * 2002-03-01 2003-09-12 Naerhi Timo Ciments au verre ionomere permettant d'ameliorer la mineralisation d'un tissu dur

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PIETAK ET AL: "Silicon substitution in the calcium phosphate bioceramics" BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 28, no. 28, 14 July 2007 (2007-07-14), pages 4023-4032, XP022153621 ISSN: 0142-9612 *
VÄLIMÄKI V V ET AL: "Molecular basis for action of bioactive glasses as bone graft substitute." SCANDINAVIAN JOURNAL OF SURGERY : SJS : OFFICIAL ORGAN FOR THE FINNISH SURGICAL SOCIETY AND THE SCANDINAVIAN SURGICAL SOCIETY 2006, vol. 95, no. 2, 2006, pages 95-102, XP002550188 ISSN: 1457-4969 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102531385A (zh) * 2012-01-17 2012-07-04 上海中山医疗科技发展公司 一种生物活性玻璃及其制备方法
CN115006598A (zh) * 2021-03-03 2022-09-06 上海交通大学医学院附属第九人民医院 掺锶硅酸钙-丝蛋白复合材料制备方法与应用

Also Published As

Publication number Publication date
WO2009019323A3 (fr) 2009-12-10

Similar Documents

Publication Publication Date Title
Baino Bioactive glasses–when glass science and technology meet regenerative medicine
Lobb et al. Bone graft substitutes: current concepts and future expectations
Jones Reprint of: Review of bioactive glass: From Hench to hybrids
Ooms et al. Trabecular bone response to injectable calcium phosphate (Ca‐P) cement
Moore et al. Synthetic bone graft substitutes
US8506985B2 (en) Bone regeneration materials based on combinations of monetite and other bioactive calcium and silicon compounds
Nandi et al. The repair of segmental bone defects with porous bioglass: an experimental study in goat
Manjubala et al. Bioactivity and osseointegration study of calcium phosphate ceramic of different chemical composition
Nandi et al. Development and applications of varieties of bioactive glass compositions in dental surgery, third generation tissue engineering, orthopaedic surgery and as drug delivery system
Bandyopadhyay‐Ghosh et al. Osteoconductivity of modified fluorcanasite glass–ceramics for bone tissue augmentation and repair
WO2012039592A1 (fr) Procede d'elaboration d'un ciment biphasé macroporeux a base de bioverre d'une apatite, bioactif, bioresorbable a usage biomedical
Pina et al. Ceramic biomaterials for tissue engineering
Jones et al. Ceramics, glasses, and glass-ceramics: Basic principles
Salinas et al. Use of bioactive glasses as bone substitutes in orthopedics and traumatology
Baino Ceramics for bone replacement: Commercial products and clinical use
O'Donnell Melt‐derived bioactive glass
Ramesh et al. Calcium-based ceramic biomaterials
Daculsi et al. The micro macroporous biphasic calcium phosphate concept for bone reconstruction and tissue engineering
WO2009019323A2 (fr) Utilisation de verre bioactif
Jones Bioactive ceramics and glasses
Griffon et al. Early dissolution of a morsellised impacted silicate‐free bioactive glass in metaphyseal defects
Hammouche et al. Calcium salts bone regeneration scaffolds: a review article
Daculsi et al. Tricalcium phosphate/hydroxyapatite biphasic ceramics
Fernandez et al. Biointegration of bone graft substiutes from osteointegration to osteotranduction
Hupa et al. Bioactive Glass S 53 P 4–From a Statistically Suggested Composition to Clinical Success

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08787722

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08787722

Country of ref document: EP

Kind code of ref document: A2